AstraZeneca’s shares spike on positive PhIII lung cancer data — but it’s not MYSTIC Submitted by admin on Fri, 05/12/2017 - 09:40 Read more about AstraZeneca’s shares spike on positive PhIII lung cancer data — but it’s not MYSTIC Source Endpoints Headline AstraZeneca’s shares spike on positive PhIII lung cancer data — but it’s not MY… News Tags AstraZeneca clinical trials durvalumab Imfinzi non-small cell lung cancer
Checkpoint inhibitors set to face off in bladder cancer Submitted by admin on Wed, 02/08/2017 - 09:48 Read more about Checkpoint inhibitors set to face off in bladder cancer Source BioPharma Dive Headline Checkpoint inhibitors set to face off in bladder cancer News Tags bladder cancer Bristol-Myers Squibb Opdivo Merck Keytruda Roche Tecentriq AstraZeneca durvalumab
AZ chief: Durvalumab's ready for a 'marketing battle' against I-O heavyweights Opdivo, Keytruda Submitted by admin on Tue, 02/07/2017 - 10:25 Read more about AZ chief: Durvalumab's ready for a 'marketing battle' against I-O heavyweights Opdivo, Keytruda Source Fierce Pharma Headline AZ chief: Durvalumab's ready for a 'marketing battle' against I-O heavyweights … News Tags immuno-oncology AstraZeneca durvalumab Pascal Soriot Merck Keytruda Bristol-Myers Squibb Opdivo
AstraZeneca angles for more competitive position in immuno-oncology Submitted by admin on Thu, 01/19/2017 - 11:19 Read more about AstraZeneca angles for more competitive position in immuno-oncology Source BioPharma Dive Headline AstraZeneca angles for more competitive position in immuno-oncology News Tags AstraZeneca immuno-oncology tremelimumab durvalumab
AstraZeneca delays PD-L1 data in rejig of phase 3 program Submitted by admin on Tue, 01/17/2017 - 10:02 Read more about AstraZeneca delays PD-L1 data in rejig of phase 3 program Source Fierce Biotech Headline AstraZeneca delays PD-L1 data in rejig of phase 3 program News Tags AstraZeneca anti-PD-L1 clinical trials tremelimumab durvalumab
Your attention, please: AstraZeneca asks for a moment of rapt silence, for a BLA acceptance? Submitted by admin on Sun, 12/11/2016 - 11:57 Read more about Your attention, please: AstraZeneca asks for a moment of rapt silence, for a BLA acceptance? Source Endpoints Headline Your attention, please: AstraZeneca asks for a moment of rapt silence, for a BL… News Tags AstraZeneca durvalumab anti-PD-L1 bladder cancer
Brace Yourself: AstraZeneca Could Be a Fourth Entrant into the PD-1/PD-L1 Drug Class Submitted by admin on Mon, 11/21/2016 - 11:39 Read more about Brace Yourself: AstraZeneca Could Be a Fourth Entrant into the PD-1/PD-L1 Drug Class Source Market Realist Headline Brace Yourself: AstraZeneca Could Be a Fourth Entrant into the PD-1/PD-L1 Drug … News Tags AstraZeneca anti-PD-L1 durvalumab Opdivo Keytruda Tecentriq Bristol-Myers Squibb Roche Merck
Here's Why AstraZeneca Dipped 14.2% in October Submitted by admin on Thu, 11/10/2016 - 10:22 Read more about Here's Why AstraZeneca Dipped 14.2% in October Source Motley Fool Headline Here's Why AstraZeneca Dipped 14.2% in October News Tags AstraZeneca AZD9412 durvalumab Brilinta
FDA slaps a partial hold on one of AstraZeneca’s crucial durvalumab programs Submitted by admin on Fri, 10/28/2016 - 10:12 Read more about FDA slaps a partial hold on one of AstraZeneca’s crucial durvalumab programs Source Endpoints Headline FDA slaps a partial hold on one of AstraZeneca’s crucial durvalumab programs News Tags FDA AstraZeneca durvalumab clinical trials head and neck cancer
Amgen's Biosimilar Approval And Astra's Anti-PD-L1 Data Submitted by admin on Sun, 09/18/2016 - 09:54 Read more about Amgen's Biosimilar Approval And Astra's Anti-PD-L1 Data Source Seeking Alpha Headline Amgen's Biosimilar Approval And Astra's Anti-PD-L1 Data News Tags Amgen biosimilars AstraZeneca anti-PD-L1 ABP 501 Humira durvalumab